WASHINGTON D.C. — Defense Secretary Pete Hegseth announced a new mandatory testosterone deficiency screening program for U.S. service members aged 30 and older, effective January 2025. The policy requires annual testosterone level screenings as part of routine periodic health assessments and aims to offer medically supervised testosterone replacement therapy to those diagnosed with deficiency.

Hegseth unveiled the initiative in a video posted to X, where he described the program as essential to maintaining the fighting force’s biological readiness. "I’m authorizing a new screening program for testosterone deficiency for our service members, ensuring you have the right testosterone levels to operate at your absolute best," he said. The post included the caption "The High-T Department of War," framing the policy within a broader narrative of optimizing warfighter performance.

Under the new directive, all service members aged 30 and older must undergo annual testosterone screenings during their standard health evaluations. Those under 30 may voluntarily opt into the screening. If medical professionals determine that a service member has clinically low testosterone levels, testosterone replacement therapy will be made available—but acceptance of treatment remains voluntary. The Pentagon has not specified when the requirement will be implemented across individual military branches or whether supplementary clinical guidance will accompany the rollout.

Hegseth emphasized that the program is not intended as a form of artificial enhancement but as a restorative measure. "This initiative, it’s not about artificial enhancement; it’s about restoring and optimizing your natural capabilities, protecting your longevity, and ensuring you have the biological foundation required to sustain the fight," he said. He added that while the Department invests heavily in weapons and platforms, "our most decisive tactical advantage will always be the individual warfighter."

He linked the policy to broader obligations of military medical care, stating, "We owe our warriors the absolute best medical care in the world, and this program delivers on that obligation." Hegseth also argued that early intervention on health markers like testosterone supports sustained combat effectiveness: "The modern battlefield is brutal and unrelenting. It requires and demands maximum psychological and mental readiness, and by addressing these health markers early, we’re keeping you on the leading edge of lethality." He asserted that optimizing performance, resilience, and long-term health is a "sacred duty" inherent to maintaining the U.S. military’s edge.

Medical and epidemiological data cited in support of the program note that testosterone deficiency can cause muscle loss, fatigue, weight gain, and sexual dysfunction. It is also associated with diabetes, cardiovascular disease, osteoporosis, and depression. Studies suggest varying prevalence rates: the American Urological Association notes that definitions of low testosterone differ across research, yielding estimates ranging from 2% to 50%. Other data indicate that roughly 5.6% of men between 30 and 79 have testosterone deficiency, while newer research finds that one in four men over age 30 show low levels.

The policy arrives rising use of related medications within the military health system. Official statistics show that active-duty troops received 108,323 prescriptions for erectile dysfunction drugs in 2024 and 108,332 in 2025, up from 92,966 in 2021. Veterans and dependents received 639,355 such prescriptions in 2025 alone. Though erectile dysfunction is not identical to testosterone deficiency, the Endocrine Society states that individuals with clinically diagnosed low testosterone often experience improved sexual function after treatment.

Recent scientific findings may underpin the program’s medical rationale. A 2023 study known as the TRAVERSE trial concluded that testosterone replacement therapy did not increase the risk of heart attacks or strokes. Additionally, the Food and Drug Administration removed black box warnings on testosterone therapies for menopause in 2024, signaling a shift in regulatory perception of hormone treatments. Outside the military, research published in Social Science and Medicine has documented a trend of young men being targeted online by wellness influencers promoting hormone testing and therapies—a context that may reflect broader cultural interest in hormonal optimization.

The screening program represents a expansion of routine military health monitoring into hormonal biomarkers previously addressed only on a case-by-case basis. By institutionalizing testosterone assessment for a large cohort—potentially hundreds of thousands of personnel aged 30 and older—the Department of Defense is aligning medical policy with performance optimization goals. The initiative responds to documented health trends within the force, including high operational stress levels that some researchers associate with hormonal changes, and emerging clinical evidence on the safety and efficacy of replacement therapy.

However, the policy also enters a contested medical landscape. With wide variation in how low testosterone is defined and diagnosed, and with background data showing substantial prescription volumes for related conditions, the program’s implementation will depend on clear clinical standards and voluntary participation safeguards. The Pentagon’s pending decisions on rollout timing and supplementary guidance will shape how service members experience and benefit from the new requirement.